Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of February 28, 2026, Centessa Pharmaceuticals plc (CNTA) has a Wall Street consensus price target of $37.33, based on estimates from 11 covering analysts. With the stock currently trading at $26.86, this represents a potential upside of +39.0%. The company has a market capitalization of $3.61B.
Analyst price targets range from a low of $31.00 to a high of $42.00, representing a 29% spread in expectations. The median target of $38.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 10 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CNTA trades at a trailing P/E of -13.0x. Analysts expect EPS to grow +9.5% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how CNTA stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for CNTA is $37.33, representing 39.0% upside from the current price of $26.86. With 11 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CNTA has a consensus rating of "Buy" based on 11 Wall Street analysts. The rating breakdown is predominantly bullish, with 10 Buy/Strong Buy ratings. The consensus 12-month price target of $37.33 implies 39.0% upside from current levels.
CNTA's current price is $26.86 with a consensus target of $37.33 (39.0% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $42 for CNTA, while the most conservative target is $31. The consensus of $37.33 represents the median expectation. These targets typically reflect 12-month expectations.
CNTA is moderately covered, with 11 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 10 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CNTA stock forecast based on 11 Wall Street analysts shows a consensus price target of $37.33, with estimates ranging from $31 (bear case) to $42 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on CNTA, with a "Buy" consensus rating and $37.33 price target (39.0% upside). 10 of 11 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CNTA analyst price targets range from $31 to $42, a 29% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $37.33 consensus represents the middle ground.